HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buijs, W. C.A.M. Articles by Corstens, F. H. M. Search for Related Content PubMed PubMed Citation Articles by Buijs, W. C.A.M. Articles by Corstens, F. H. M.

Dosimetric Evaluation of Immunoscintigraphy Using Indium-111-Labeled Monoclonal Antibody Fragments in Patients with Ovarian Cancer

Departments of Nuclear Medicine and Obstetrics and Gynecology, University Hospital Nijmegen, Nijmegen, The Netherlands

Correspondence: For reprints contact: W.C.A.M. Buijs, MSc, Dept. Nuclear Medicine, University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands.

ABSTRACT

This study reports the biodistribution and dosimetry for a monoclonal antibody against ovarian carcinoma. Eight patients received 140 MBq ¹¹¹In-OV-TL 3 F(ab')₂; thereafter gamma camera imaging was performed daily up to 96 hr. By using the conjugated view counting method, activity in the organs was quantitated by phantom calibration and by whole-body measurements using a whole-body counter with the conjugated view counting method. Red bone marrow uptake was derived from regions of interest over the lumbar vertebrae and iliac crest. In both methods, organ uptake varied only slightly with time, having a mean value of approximately 18%, 4%, 6% and 17% of the injected dose in the liver, spleen, kidneys and red bone marrow, respectively. The mean radiation dose to these organs was 0.9, 1.5, 1.2 and 0.5 mGy/MBq. The effective dose equivalent was 0.4 mSv/MBq. In this study, two different methods of uptake calculations, result in similar values of organ uptake.

This article has been cited by other articles:

				C. P. Bleeker-Rovers, H. J.J.M. Rennen, O. C. Boerman, A. B. Wymenga, E. P. Visser, J. H. Bakker, J. W.M. van der Meer, F. H.M. Corstens, and W. J.G. Oyen 99mTc-Labeled Interleukin 8 for the Scintigraphic Detection of Infection and Inflammation: First Clinical Evaluation J. Nucl. Med., March 1, 2007; 48(3): 337 - 343. [Abstract] [Full Text] [PDF]

				J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883. [Abstract] [Full Text] [PDF]

				A. H. Brouwers, W. C.A.M. Buijs, P. F.A. Mulders, P. H.M. de Mulder, W. J.M. van den Broek, C. Mala, E. Oosterwijk, O. C. Boerman, F. H.M. Corstens, and W. J.G. Oyen Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response Clin. Cancer Res., October 1, 2005; 11(19): 7178s - 7186s. [Abstract] [Full Text] [PDF]

				A. H. Brouwers, W. C. A. M. Buijs, E. Oosterwijk, O. C. Boerman, C. Mala, P. H. M. De Mulder, F. H. M. Corstens, P. F. A. Mulders, and W. J. G. Oyen Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison Clin. Cancer Res., September 1, 2003; 9(10): 3953S - 3960. [Abstract] [Full Text] [PDF]

				Y. Arano, Y. Fujioka, H. Akizawa, M. Ono, T. Uehara, K. Wakisaka, M. Nakayama, H. Sakahara, J. Konishi, and H. Saji Chemical Design of Radiolabeled Antibody Fragments for Low Renal Radioactivity Levels Cancer Res., January 1, 1999; 59(1): 128 - 134. [Abstract] [Full Text] [PDF]